Another China-Developed PD-1 Inhibitor Makes Its Case in NSCLC

(MedPage Today) -- Adding the investigational PD-1 checkpoint inhibitor toripalimab to chemotherapy in first-line significantly improved progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients without EGFR/ALK mutations...